Recent Advances to Augment NK Cell Cancer Immunotherapy Using Nanoparticles

Area of Science:

• Immunology
• Oncology
• Nanomedicine

Background:

• Natural killer (NK) cells are innate immune cells crucial for targeting cancer cells that evade immune surveillance.
• NK cell immunotherapy has shown potential in preclinical and clinical settings, with 288 trials in 2021 for various malignancies.
• Despite progress, clinical outcomes remain limited by factors such as the immunosuppressive tumor microenvironment and inadequate NK cell function.

Purpose of the Study:

• To review recent clinical trials in NK cell cancer immunotherapy.
• To discuss the persistent challenges hindering NK cell therapy efficacy.
• To explore the potential of nanotechnology in augmenting NK cell immunotherapy.

Main Methods:

• Review of current clinical trials investigating NK cell immunotherapy.
• Analysis of limitations in NK cell-mediated cancer treatment.
• Examination of nanoparticle-based strategies to enhance NK cell functions.

Main Results:

• NK cell immunotherapy faces challenges including immune suppression, low NK cell activity, and poor tumor infiltration.
• Nanoparticles offer versatile applications in drug delivery, imaging, and modifying physicochemical properties to enhance NK cell therapy.
• Nanotechnology presents a promising avenue to overcome current therapeutic limitations.

Conclusions:

• Advancements in nanotechnology and nanomedicine are crucial for overcoming NK cell immunotherapy challenges.
• Targeted delivery and functional enhancement of NK cells using nanoparticles can significantly improve cancer treatment outcomes.
• Further research into nanoparticle-mediated augmentation is essential for realizing the full potential of NK cell cancer immunotherapy.